Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Immune Tolerance Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PD-L2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PD-L2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View PD-L2 Products |
| Gene Delivery | PD-L2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and flow cytometry validation. |
View PD-L2 Products |
| Benchmark Ab | Anti-PD-L2 Recombinant Antibody Sequence-verified benchmark positive control for binding and blocking assays. |
View PD-L2 Products |
| Validator | PD-L2 siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View PD-L2 Products |
| Related Target A | PD-1 (PDCD1) Primary receptor for PD-L2. Crucial for establishing screening assays for checkpoint inhibitors. |
View PD-1 Products |
| Related Target B | PD-L1 (CD274) Sister ligand sharing the PD-1 pathway. Essential for cross-reactivity and selectivity profiling. |
View PD-L1 Products |
| Related Target C | RGMb (Repulsive Guidance Molecule b) Alternative receptor for PD-L2, mediating respiratory tolerance and mucosal immunity. |
View RGMb Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Human vs. Cyno/Mouse) | Human, Cynomolgus, and Mouse PD-L2 recombinant proteins available with >95% purity verified by SDS-PAGE. |
| Ligand selectivity & off-target counter screening | Homolog panel (PD-L1, B7-H3, B7-H4) strictly verified by mass spectrometry and sequence analysis. |
| Lack of reliable positive controls | Clinical-grade benchmark biosimilar antibodies included for assay standardization. |
| Conformation-dependent binding validation | Lentiviral vectors for stable cell-surface expression, preserving native tertiary structure. |
Live PD-L2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PD-L2 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum PD-1/PD-L1 blockade to selective or dual-targeting strategies. While PD-L1 has dominated the first wave of immune checkpoint inhibitors, PD-L2 expression on specific tumor types (such as head and neck squamous cell carcinoma, triple-negative breast cancer, and certain lymphomas) and its distinct interaction with RGMb make it a critical node for overcoming PD-1/PD-L1 resistance. As next-generation therapies reach the clinic, the next wave of R&D is targeting dual PD-L1/PD-L2 bispecific antibodies, antibody-drug conjugates (ADCs) targeting PD-L2-positive niches, and selective small-molecule inhibitors designed to disrupt the PD-1/PD-L2 interface without triggering pulmonary toxicity associated with RGMb disruption.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibodies (e.g., PD-L1/PD-L2) | Invenra, F-star Therapeutics | Solid Tumors, Refractory Non-Small Cell Lung Cancer (NSCLC) | Dual-binding kinetics validation (Requires high-purity, monomeric PD-L2 and PD-L1 proteins) |
| Monoclonal Antibodies (Selective PD-L2) | GlaxoSmithKline, Merck & Co. | Triple-Negative Breast Cancer (TNBC), Head & Neck Cancer | Epitope mapping and ligand-blocking assays (Requires sequence-verified clinical benchmark antibodies) |
| Small Molecule Inhibitors | Aurigene, Bristol Myers Squibb | Advanced Solid Malignancies | High-throughput screening of protein-protein interaction (PPI) disruptors (Requires stable HEK293-expressed PD-L2) |